Abstract
Hepatocellular carcinoma (HCC) prognosis is very poor, its early treatment is of the utmost importance. Glypican-3 (GPC-3), a membrane-associated heparan sulfate proteoglycan, plays a crucial role in cell proliferation and metastasis, particularly in progression. GPC-3 mediated oncogenesis involves signaling pathways during the malignant transformation of hepatocyte carcinogenesis, with an increasing expression of GPC-3 observed from non-cancerous- to cancerous-tissues, with brown granule-like staining localized in tumor parts of atypical hyperplasia and HCC formation. GPC-3 expression in HCC tissues or circulating blood was associated with tumor size or HBV infection. Circulation of GPC-3-mRNA was detected in HCC patients with relation to TNM stage, periportal cancerous embolus, and extra-hepatic metastasis. After hepatoma, cells were transfected with shRNA, GPC-3 expression or proliferation was inhibited with promoting apoptosis, cell cycle arrested in G1 phase, alteration of hepatoma cell migration and invasion behaviors with down-regulation of β-catenin, IGF-II, and VEGF, and growth of nude mice xenograft tumors was significantly suppressed with the decreases in β -catenin, p-GSK3β, and cyclinD1 expression, suggesting that GPC-3 not only is a specific biomarker for HCC diagnosis, but also is a valuable molecular-target for HCC gene therapy.
Keywords: Diagnosis, glypican-3, hepatocellular carcinoma, signal pathways, targeted-therapy.
Mini-Reviews in Medicinal Chemistry
Title:Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma
Volume: 14 Issue: 14
Author(s): Zhizhen Dong, Min Yao, Li Wang, Junling Yang and Dengfu Yao
Affiliation:
Keywords: Diagnosis, glypican-3, hepatocellular carcinoma, signal pathways, targeted-therapy.
Abstract: Hepatocellular carcinoma (HCC) prognosis is very poor, its early treatment is of the utmost importance. Glypican-3 (GPC-3), a membrane-associated heparan sulfate proteoglycan, plays a crucial role in cell proliferation and metastasis, particularly in progression. GPC-3 mediated oncogenesis involves signaling pathways during the malignant transformation of hepatocyte carcinogenesis, with an increasing expression of GPC-3 observed from non-cancerous- to cancerous-tissues, with brown granule-like staining localized in tumor parts of atypical hyperplasia and HCC formation. GPC-3 expression in HCC tissues or circulating blood was associated with tumor size or HBV infection. Circulation of GPC-3-mRNA was detected in HCC patients with relation to TNM stage, periportal cancerous embolus, and extra-hepatic metastasis. After hepatoma, cells were transfected with shRNA, GPC-3 expression or proliferation was inhibited with promoting apoptosis, cell cycle arrested in G1 phase, alteration of hepatoma cell migration and invasion behaviors with down-regulation of β-catenin, IGF-II, and VEGF, and growth of nude mice xenograft tumors was significantly suppressed with the decreases in β -catenin, p-GSK3β, and cyclinD1 expression, suggesting that GPC-3 not only is a specific biomarker for HCC diagnosis, but also is a valuable molecular-target for HCC gene therapy.
Export Options
About this article
Cite this article as:
Dong Zhizhen, Yao Min, Wang Li, Yang Junling and Yao Dengfu, Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma, Mini-Reviews in Medicinal Chemistry 2014; 14 (14) . https://dx.doi.org/10.2174/1389557515666150101105135
DOI https://dx.doi.org/10.2174/1389557515666150101105135 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
Current Cancer Drug Targets Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Enhanced Intracellular Delivery of Curcumin by Chitosan-Lipoic Acid as Reduction-Responsive Nanoparticles
Current Pharmaceutical Biotechnology Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Recent Developments in the Field of Anticancer Platinum Complexes
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Cyclodextrin Complexation of Meclizine Hydrochloride and its Influence on the Solubility for its Repurposing
Drug Delivery Letters Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design